Photocure ASA
Beyond's analysis on Photocure ASA
- — Photocure ASA posted modest Q2 2026 revenue growth and stable earnings, underscoring resilient demand for its Hexvix/Cysview bladder cancer imaging agents
- — Photocure ASA posts modest revenue growth and flat adjusted EBITDA in Q2 2026